Alumis Inc. shares surge after positive trial results for Envudeucitinib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 06 Jan 26
Alumis Inc. shares surged by 121.78% in pre-market trading, reaching a 52-week high.
This remarkable increase is attributed to Alumis achieving positive Phase 3 results for Envudeucitinib, with 65% of patients meeting PASI 90, indicating significant efficacy in treating moderate-to-severe plaque psoriasis. The company plans to submit a New Drug Application to the FDA in the second half of 2026, which could open new revenue streams and solidify its market position.
The strong performance reflects investor optimism regarding the potential of Envudeucitinib and its implications for future treatment options in immune-mediated diseases.
Analyst Views on ALMS
Wall Street analysts forecast ALMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is 37.67 USD with a low forecast of 32.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.710
Low
32.00
Averages
37.67
High
50.00
Current: 27.710
Low
32.00
Averages
37.67
High
50.00
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
